Similarly, [18F]FSPG PET captures xCT/NRF2 activity, and heterogeneous retention in NSCLC tumors offers a complementary biomarker for therapeutic stratification [112,235]. This evidence concerns the gene NFE2L2 and non-small cell lung carcinoma.